CANTAB


Also found in: Dictionary, Acronyms, Wikipedia.

CANTAB

Cambridge Neuropsychological Test Automated Battery. A tool for assessing cognitive deficits in neurodegenerative disease and brain damage, which consists of 13 interrelated tests of memory, attention, and executive function, administered via a touchscreen PC. The tests are language and largely culture free, and are used for early detection and routine screening of Alzheimer's disease.
References in periodicals archive ?
Jackson was a student at Hampshire College in Amherst when she started traveling to Boston to enter slams at the Cantab Lounge.
5m) upfront payment plus milestones and royalties from North American licensing deal with Millennium Pharmaceuticals, Inc for novel DNA targeting agent program * Collaborations by joint venture Phogen with Genencor (up to 15m pounds (US$21m)) and Cell Genesys (undisclosed) for VP22 technology * Start of combined 'Prime-Boost' Phase II trials for cancer program vaccines TA-CIN and TA-HPV * Anti-nicotine addiction vaccine TA-NIC entry to Phase I clinical trials * Merger with Cantab completed April 2001 Financial Highlights * Cash and liquid resources at 31 December 2001 24.
And CanTab Pharmaceuticals jumped another 25 to 144p as investment banks speculated that the group could fetch as much as 200p a share should a bid come for the biotech company.
But biotechnology company Cantab Pharmaceuticals saw its shares lose more than 67 per cent, or 156p, to 761/1p, after announcing pharmaceuticals giant SmithKline Beecham had dropped its backing for a new genital wart vaccine because it had failed clinical trials.
Cambridge- based company Cantab Pharmaceuticals today announced the results of the first phase of clinical trials on TA-CD, which it described as ''encouraging''.
Ionix also announced the appointment of Kelly Chessum as Financial Controller, formerly chief accountant with Cantab Pharmaceuticals plc, which was acquired by Xenova Group plc in 2001, where she also served as chief accountant.
Following the merger with Cantab, Xenova is a stronger company with a broad pipeline of high value opportunities.
CanTab, the troubled biotech, tipped in this colum as a buy at 82p last week, soared 25per cent to 115p as hopes of a bidder were met.
CANTAB has been shown in more than 150 peer-reviewed publications to be a sensitive and reliable tool for the measurement of drug and disease effects on cognition and psychological function.
He joined Xenova following the merger with Cantab Pharmaceuticals plc (Cantab) in April 2001.
Cantab Pharma- ceuticals have had their fair share of problems over the past few months.
Completion of merger with Cantab Pharmaceuticals plc